The Zurich OVID trial

The OVID trial was initiated in 2020, at the beginning of the pandemic, with the aim to demonstrate superiority of enoxaparin as compared to standard of care for primary thromboprophylaxis in ambulatory patients with coronavirus disease. The trial protocol can be found here. 

The trial was stopped early for futility, and the results of the trial were published in Lancet Hematology here.

An individual patient data (IPD) meta-analysis in planned, in which the data of the OVID trial and the ETHIC trial (a similar trial from UK) will be pooled using a one-step design.